Nu-Med Plus (NUMD) Operating Income (2012 - 2025)
Nu-Med Plus (NUMD) reported Operating Income of -$9761.0 for Q4 2025, down 5.02% on a YoY basis from -$10277.4 in Q4 2024, and up 3.12% sequentially from -$10075.0 in Q3 2025.
Nu-Med Plus (NUMD) Operating Income (2012 - 2025) Analysis & Trends
Nu-Med Plus (NUMD) has 14 years of Operating Income data on file, last reported at -$9761.0 in Q4 2025.
- For the quarter ending Q4 2025, Operating Income fell 5.02% year-over-year to -$9761.0; the trailing twelve-month figure through Dec 2025 stood at -$48955.0 (up 22.7% YoY), and the FY2025 full-year result was -$48955.0, up 22.7% from the prior year.
- Operating Income advanced to -$9761.0 in Q4 2025, from -$10075.0 in the prior quarter.
- In the past five years, Operating Income ranged from a high of -$6394.0 in Q4 2022 to a low of -$356748.0 in Q1 2021.
- A 5-year average of -$62721.2 and a median of -$21826.0 in 2023 frame the typical range for Operating Income.
- Across the five-year window, Operating Income surged 94.31% in 2022 and plunged 765.44% in 2023, its largest moves.
- Tracing NUMD's Operating Income over 5 years: stood at -$112341.0 in 2021, then surged by 94.31% to -$6394.0 in 2022, then sank by 765.44% to -$55336.0 in 2023, then surged by 83.2% to -$9294.0 in 2024, then fell by 5.02% to -$9761.0 in 2025.
- Business Quant data shows NUMD's Operating Income at -$9761.0 in Q4 2025, -$10075.0 in Q3 2025, and -$10419.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 182.44 Bn | 175.14 Bn | 6.27 Bn | 1.35 Bn |
| 2 | Stryker | 128.91 Bn | 126.03 Bn | 3.81 Bn | 936.00 Mn |
| 3 | Medtronic | 108.67 Bn | 99.45 Bn | 6.41 Bn | 1.87 Bn |
| 4 | Boston Scientific | 68.45 Bn | 67.00 Bn | 3.61 Bn | 1.10 Bn |
| 5 | Edwards Lifesciences | 47.59 Bn | 43.92 Bn | 1.29 Bn | 477.60 Mn |
| 6 | Dexcom | 28.59 Bn | 27.48 Bn | 750.30 Mn | 255.30 Mn |
| 7 | GE HealthCare Technologies | 28.53 Bn | 26.24 Bn | 1.98 Bn | 515.00 Mn |
| 8 | Smith & Nephew | 26.95 Bn | 26.37 Bn | - | - |
| 9 | Koninklijke Philips | 25.42 Bn | 22.30 Bn | 2.07 Bn | 282.15 Mn |
| 10 | Nu-Med Plus | 1.67 Mn | 1.67 Mn | - | -9,761.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -9,761.00 |
| Sep 30, 2025 | -10,075.00 |
| Jun 30, 2025 | -10,419.00 |
| Mar 31, 2025 | -18,700.00 |
| Dec 31, 2024 | -9,294.00 |
| Sep 30, 2024 | -17,417.00 |
| Jun 30, 2024 | -16,040.00 |
| Mar 31, 2024 | -20,579.00 |
| Dec 31, 2023 | -55,336.00 |
| Sep 30, 2023 | -15,146.00 |
| Jun 30, 2023 | -23,073.00 |
| Mar 31, 2023 | -26,971.00 |
| Dec 31, 2022 | -6,394.00 |
| Sep 30, 2022 | -58,050.00 |
| Jun 30, 2022 | -58,070.00 |
| Mar 31, 2022 | -59,653.00 |
| Dec 31, 2021 | -112,341.00 |
| Sep 30, 2021 | -118,366.00 |
| Jun 30, 2021 | -251,990.00 |
| Mar 31, 2021 | -356,748.00 |